You are here: Industry Insights > Sorrento Therapeutics

News List

100 public pharma and CMOs took PPP COVID-19 small business loans: GlobalData expresspharma
September 04, 2020
The two largest, Sorrento Therapeutics and a US-based CMO subsidiary of Japanese firm NOF Corp, had market caps in the billions of dollars, while a further 12 had market caps over $200 million.
Potential Anti-SARS-CoV-2 Antibody Able to Inhibit In Vitro Virus Infection in Preclinical Studies americanpharmaceuticalreview
May 19, 2020
Sorrento Therapeutics announced anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration.
Sorrento’s antibody completely blocks Covid-19 in-vitro pharmaceutical-technology
May 19, 2020
Sorrento Therapeutics has reported that its Covid-19 therapeutic antibody candidate, STI-1499, can completely block the viral infection in-vitro during preclinical studies.
Sorrento forms alliance for preclinical testing of Covid-19 drugs pharmaceutical-technology
April 02, 2020
Sorrento Therapeutics has signed a research testing agreement with the University of Texas Medical Branch at Galveston in the US for preclinical studies of Covid-19 drug candidates.
Sorrento Therapeutics to develop cellular vaccine for Covid-19 pharmaceutical-technology
March 27, 2020
Sorrento Therapeutics has started a programme to develop a decoy cellular vaccine, STI-6991, against Covid-19 coronavirus infection.